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Objectives: “PAULA’s” test (Protein Assays Utilizing Lung cancer Analytes) is a novel multiplex immunoassay blood
test that incorporates both tumor antigens and autoantibodies to determine the risk that lung cancer (LC) is
present in individuals from a high-risk population. The test’s performance characteristics were evaluated in a study
using 380 retrospective clinical serum samples.
Methods: PAULA’s test is performed on the Luminex xMAP technology platform, and detects a panel of 3 tumor
antigens (CEA, CA-125, and CYFRA 21–1) and 1 autoantibody marker (NY-ESO-1). A training set (n = 230) consisting of
115 confirmed diagnoses of non-small cell lung carcinoma (NSCLC) cases and 115 age- and smoking history-matched
controls was used to develop the LC predictive model. Data from an independent matched validation set (n = 150)
was then used to evaluate the model developed, and determine the ability of the test to distinguish NSCLC cases
from controls.
Results: The 4-biomarker panel was able to discriminate NSCLC cases from controls with 74% sensitivity, 80% specificity,
and 0.81 AUC in the training set and with 77% sensitivity, 80% specificity, and 0.85 AUC in the independent validation
set. The use of NY-ESO-1 autoantibodies substantially increased the overall sensitivity of NSCLC detection as compared
to the 3 tumor markers alone. Overall, the multiplexed 4-biomarker panel assay demonstrated comparable performance
to a previously employed 8-biomarker non-multiplexed assay.
Conclusions: These studies confirm the value of using a mixed panel of tumor antigens and autoantibodies in the early
detection of NSCLC in high-risk individuals. The results demonstrate that the performance of PAULA’s test makes
it suitable for use as an aid to determine which high-risk patients need to be directed to appropriate noninvasive
diagnostic follow-up testing, especially low-dose CT (LDCT).
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In the United States, LC is the third most commonly di-
agnosed cancer, with approximately 224,210 new cases
expected in 2014 [1]. Moreover, LC accounts for more
combined cancer-related deaths in men and women than
any other cancer (approximately 27% of all cancer-
related deaths in a recent study) [1]. Cigarette smoking
remains the single most important determinant of LC
susceptibility and is responsible for 87% of LC deaths
among men and 70% of LC deaths among women [2].* Correspondence: vdoseeva@2020gene.com
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unless otherwise stated.The relative risk of death from LC is about 26 times
higher in female smokers and 25 times higher in male
smokers compared to lifelong nonsmokers [3]. Risk
increases with quantity and duration of cigarette con-
sumption [4].
While the overall survival rate for LC is 15%, a survival
rate of 70–80% can be achieved when detected early in
individuals with localized cancer [5]. Yet only 15% of
LCs are diagnosed at this early stage [1]. These statistics
imply a compelling unmet need for new noninvasive
tests for the early detection of LC. CT is the most com-
monly used method for regular screening for the early
detection of LC in clinical settings [6]. Despite itsl. This is an Open Access article distributed under the terms of the Creative
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CT has many drawbacks that suggest its applicability
will be limited as a stand-alone detection method-
ology. These problems include a high false-positive
rate (including the inability to unambiguously distin-
guish benign nodules that can involve expensive invasive
follow-up procedures); the high cost of testing; and the
danger of cumulative diagnostic radiation exposure with
repeated testing [8-10]. Another major drawback of low-
dose computed tomography (LDCT) scanning is over-
diagnosis, which has been estimated to be more than
18.5% for all LCs [11].
For these reasons, the development and validation of a
robust and cost-effective early-stage blood test to com-
plement imaging-based diagnosis is essential. The litera-
ture reports a variety of approaches that have been
pursued for nearly 2 decades to reach this end, including
(1) proteomics-based methods, (2) characterization of
genomic expression, (3) monitoring gene methylation,
(4) detection of mitochondrial DNA mutations or chromo-
somal abnormalities, and (5) the detection of such blood-
based biomarkers as tumor-derived proteins, microRNA,
or autoantibodies arising from a patient’s immune response
to tumor cells [12-14]. A number of recent review papers
indicate blood-based biomarker detection is the most
highly developed of these approaches and support the con-
cept that these biomarkers can be used to detect early stage
NSCLC and complement CT imaging [15-18].
Many investigators have demonstrated that tumor an-
tigens are present in the serum or plasma of patients
with LC at all stages. Technologies used to detect and
quantify tumor protein expression have varied from
traditional ELISA methodology [19-21], to electrochemi-
luminescence immunoassay [22,23], modified aptamers
(so-called slow off-rate modified aptamers [SOMAmers])
[24,25], MALDI MS proteomic analysis [26,27], and
multiplex Luminex assays [28,29]. Among the most
promising approaches is an ELISA-based test [20] in
which 4 serum proteins (CEA, RBP, 1-antitrypsin, and
SCC) were used. In a validation set consisting of 97 sam-
ples (49 cancers and 48 controls), this panel demonstrated
the ability to distinguish LC with 77.8% sensitivity and
75.4% specificity from matched control patients.
In 2010, Ostroff et al. [24] reported results from a pro-
prietary proteomic assay based on SOMAmers, in which
a 12 protein NSCLC proteomic signature in serum was
identified. This 12-protein panel (cadherin-1, CD30 lig-
and, endostatin, HSP90α, LRIG3, MIP-4, pleiotrophin,
PRKCI, RGM-C, SCF-sR, sL-selectin, and YES) discrimi-
nated NSCLC from controls with 89% sensitivity and 83%
specificity in a blinded validation study (341 samples).
Results from another multiplex Luminex-based assay
for the detection of early stage NSCLC using protein
biomarkers was reported by Bigbee et al. in 2012 [28]. Inthis study, the authors evaluated the combined effect
of 10 protein biomarkers (prolactin, transthyretin,
thrombospondin-1, E-selectin, C-C motif chemokine 5,
macrophage migration inhibitory factor, plasminogen acti-
vator inhibitor, receptor tyrosine-protein kinase, CYFRA
21–1, and serum amyloid A) for the ability to distinguish
LC from controls. The assay’s discriminative performance
was demonstrated in a blinded verification set consisting
of 60 samples (73.3% sensitivity at 93.3% specificity). Based
on the observed panel performance, the authors con-
cluded that these biomarkers could potentially improve in-
terpretation of CT images in the setting of suspicious
pulmonary nodules.
Several publications have appeared in recent years
documenting incorporation of protein biomarkers into
CT imaging models [27,30-32]. Yildiz et al. [26] identi-
fied a serum proteomic signature to distinguish LC cases
from matched controls with MALDI MS technology.
Their MALDI MS proteomic analysis reached an overall
accuracy of 72.6 %, a sensitivity of 58%, and a specificity
of 85.7% in a blinded test set. A later study [27] demon-
strated that this proteomic signature was able to dis-
criminate LC from benign indeterminate lung nodules.
These studies were among the first to demonstrate the
additive value of protein biomarkers to pulmonary nod-
ules imaging results.
In addition to detecting tumor antigens directly, de-
tecting autoantibodies to tumor antigens has also been
extensively investigated as an alternative approach for
the early detection of LC [33-36]. Use of autoantibody
detection is very promising, since autoantibodies have
been shown to be present and detectable in patient
blood as much as 5 years before some patients present
with symptoms [37-39]. One of the first studies on the
use of autoantibodies for early detection of LC was de-
scribed in publications by Hanash et al. [39-41]. The au-
thors identified 3 autoantibodies (annexin 1, LAMR 1,
and 14-3-3 theta) that are found prior to diagnosis in
about 30% of the LC patients [39]. This autoantibody
panel yielded 55% sensitivity at 95% specificity and 0.838
AUC in discriminating LC at the preclinical stage from
matched controls. Zhong et al. [37] reported a panel of 5
autoantibodies that yielded 91.3% sensitivity and 91.3%
specificity in the prediction of NSCLC cases, although
with a limited sample set, and not including patients
with nonmalignant pulmonary nodules. Farlow et al. [42]
identified a 6-autoantibody panel consisting of IMPDH,
phosphoglycerate mutase, ubiquillin, annexin I, annexin
II, and HSP70-9B that can detect NSCLC among several
patient cohorts including benign lung diseases (chronic
obstructive pulmonary disease [COPD]/asthma) and be-
nign pulmonary nodules. Their Luminex-based assay
showed impressive performance characteristics: an AUC
of 0.964, a sensitivity of 94.8%, and a specificity of 91.1%,
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autoantibody panels.
Several publications from Oncimmune Corp.
(Nottingham, UK) provided further evidence supporting
the use of autoantibodies for early detection of NSCLC
[43-46]. Murray et al. [43] first described a laboratory-
developed test for the early detection of LC based on the
presence of 6 autoantibodies (CAGE, GBU4-5, HuD,
MAGE A4, NY-ESO-1, p53, and SOX) in the serum of
heavy smokers. The clinical performance of this test has
been confirmed in research studies and in clinical set-
tings yielding a specificity of 82-91% and a sensitivity of
37-41% [44-46]. Overall, the development of these tests
suggests that autoantibodies can be used as effective bio-
markers in the detection of NSCLC. However, the data
also indicate that to achieve significant sensitivity and
thus broader clinical acceptance, either a larger autoanti-
body panel or a panel including other biomarkers will be
required.
As shown, there is a rapidly growing literature on both
tumor proteins and autoantibodies as biomarkers for the
early detection of LC. Tumor protein biomarkers and
autoantibody biomarkers are measurable in the blood of
individuals with various forms of solid tumors and may
be detected before the appearance of clinical symptoms
in late-stage disease [17,37-39]. Interestingly, no publica-
tions can be found in the literature that describe diag-
nostic assays using mixed panels of tumor markers and
autoantibodies. The use of such a mixed panel, if prop-
erly selected, could have the benefit of combining the
superior sensitivity of protein biomarkers with the
high specificities observed in some of the autoantibody
studies.
The objective of this study was to evaluate the per-
formance of our dual analyte PAULA’s test with early
stages of NSCLC in order to confirm the ability of our
mixed biomarker panel to identify early tumors in high-
risk patients where disease is curable. One goal was to
evaluate whether a combination of tumor protein and
autoantibody detection will raise the performance level
of a diagnostic panel. Here we report a new retrospective
study of PAULA’s test using a total of 380 patients from
3 cohorts consisting of 190 confirmed diagnoses of LC
and 190 age- and smoking history-matched controls.
Overall, the results show that our 4-biomarker panel
was able to discriminate early-stage NSCLC cases from
controls with 74% sensitivity, 80% specificity, and 0.81
AUC in the training set (n = 230) and with 77% sensitiv-
ity, 80% specificity, and 0.85 AUC in the independent
validation set (n = 150). We believe that the performance
of PAULA’s test, as well as its simple and easy-to-use
format, makes it a viable candidate assay for use as an
aid to determine which high-risk patients need to be di-
rected to appropriate diagnostic CT scanning, due to itsreduced false-positive rate, low cost, and reduced risk




All the cancer and normal control samples used in this
study were IRB-approved, consented serum samples that
were purchased from Clinical Research Center of Cape
Cod, Inc. (Cape Cod, MA) and Asterand (Detroit, MI).
Lung cancer serum samples were collected at 3 different
United States sites and in 3 European countries (Ukraine,
Russia, and Romania) to control for pre-analytical variabil-
ity. All of the lung cancer samples were collected at physi-
cians’ offices or hospitals. Many of the control samples
were collected at Cape Cod Clinical Research center. Not
all of the cases and controls from the US were matched on
a site-specific basis, which may be a source of pre-analytic
variability.
All NSCLC serum samples were within the PAULA’s
test acceptance criteria: patients 50 years of age or older
who were current or former smokers with a smoking
history of greater than 20 packs per year and less than
15 years of smoking cessation. Diagnosis confirmation
for the NSCLC cohort was obtained from surgical path-
ology reports.
The control cohort was selected on the basis of similar
demographic characteristics (with respect to age and
gender) to the NSCLC cohort. The control serums were
from healthy volunteers matched for smoking history of
greater than 20 packs per year. The control group had
no evidence of any current or prior cancer.
Additional control serum samples with benign lung
diseases and other cancers were provided by Dr. S.
Radulovich and were collected in her Clinical Laboratory
Improvement Amendments (CLIA) laboratory (Bel Air,
MD) in accordance with IRB protocol and CLIA regula-
tions. This cohort comprised 81 serum samples from pa-
tients with nonmalignant diseases (e.g., COPD, asthma,
bronchitis, pulmonary fibrosis, pneumonia, emphysema,
chronic inflammation, etc.) and cancers other than
NSCLC (e.g. myeloma, breast and colon cancers).
Multiplex assay
Multiplexed serum immunoassays were performed using
the xMAP technology platform (Luminex Corporation,
Austin, TX). Commercially available reagents from
Luminex, and Millipore, Inc. as well as reagents de-
veloped in house (20/20 Gene Systems, MD) were used.
MagPlex-carboxylated polystyrene beads were purchased
from Luminex. MagPlex beads with conjugated antibodies
against carbohydrate antigen 125 (CA125) and CYFRA
21–1, as well as detection antibodies for CEA, CA125, and
CYFRA 21–1 proteins were purchased from Millipore, Inc.
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(Cambridge, MA).
Luminex bead coupling
Covalent coupling of the CEA capture antibodies to the
microspheres was done by the procedures recommended
by Luminex Corp. In short, 5x105 microspheres were
dispersed by vortexing, washed with 100 μL of deionized
water, and resuspended in a microtiter tube with 80 μL
activation buffer (100 mM monobasic sodium phos-
phate, pH 6.2, Sigma). To activate the microspheres
10 μL of 50 mg/mL sulfo-NHS (EZ-Link sulfo-N-
hydroxysuccinimide ester, Thermo Scientific) and 10 uL
of 50 mg/mL EDC (1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride, Thermo Scientific) were
added to the beads. The bead suspension was incubated
in the dark for 20 min at room temperature. Following
incubation the activated beads were washed twice in
coupling buffer (0.05 M MES, pH 5.0, Sigma) and resus-
pended in 100 μL of the same buffer. 5 μg of anti-CEA
antibody (Abcam) was added to the mixture and the re-
action was incubated for 2 hours at room temperature
in the dark with continuous shaking. The microspheres
were then washed twice with PBS containing 0.1% of
BSA, 0.02% Tween-20, and 0.05% sodium azide, pH 7.4,
counted using the MAGPIX instrument, and stored in
the dark at 4°C.
Recombinant NY-ESO-1 protein was obtained from
Thermo Fisher Scientific, Inc. (Rockford, IL). It was con-
jugated with MagPlex microspheres (Luminex Corp.)
using a slightly different bead coupling protocol than de-
scribed above. 2.5 μg of recombinant NY-ESO-1 protein
was added to 1.25x106 microspheres in 200 μL 0.05 M
MES buffer, pH 5 (Sigma) and incubated for 2 hours at
room temperature in the dark. The mixture was subse-
quently combined with 20 μL of 1 mg/mL EDC. Follow-
ing overnight incubation at room temperature in the
dark a total of 4 washes with 1 mL of PBS/1% BSA/0.2%
Tween-20/0.04% sodium azide were performed. The con-
jugated beads were resuspended in 500 μL of blocking/
storage buffer (PBS-TBN contains 0.1% of bovine serum al-
bumin, 0.02% tween-20, and 0.05% sodium azide, pH 7.4)
and stored at 2–8°C in the dark.
Tumor marker multiplexed serum immunoassay
Multiplexed serum immunoassays were performed using
the xMAP technology platform (Luminex Corp.). Sam-
ples were assayed in triplicate. Each serum sample was
incubated overnight at 4°C with the mixture of approxi-
mately 800 capture antibody-conjugated magnetic mi-
crospheres per protein analyte per well in 96-well
microtiter plate (Millipore). Following washing with
PBST buffer, the antigen-antibody complex was incu-
bated with the biotin-conjugated detection antibodies(Millipore) for 1 hour at room temperature with con-
stant agitation. Finally, the complex was incubated with
streptavidin-phycoerythrin for 30 minutes in the dark with
agitation. The resulting bead complex was again washed
3 times, resuspended in Drive Fluid (Luminex reading
buffer), and analyzed using the MAGPIX instrument.
For each analyte, median fluorescence intensity (MFI)
values were calculated using Luminex xPONENT software.
All biomarker protein concentrations were calculated using
a 5-parametric curve fit as part of the xPONENT software.
The calculated protein concentration values were used for
the subsequent analysis.
Autoantibodies serum immunoassay
Briefly, each serum sample was incubated for 1 hour
with approximately 1,000 NY-ESO-1-conjugated mag-
netic microspheres per well in 96-well microplate. The
plates were washed 3 times with PBS-T wash buffer
(0.01 M phosphate buffered saline with 0.05% Tween-20,
pH7.4), then the immobilized autoantibodies-NY-ESO-1
protein complexes were incubated with goat anti-human
IgG conjugated to R-Phycoerythrin for 30 min at room
temperature on a plate shaker. Following 3 washes with
PBN-T buffer (phosphate-buffered saline with 0.2%
Tween-20, pH 7.4), complexes were resuspended in the
same buffer and run on the MAGPIX system.
In the absence of available autoantibody concentration
standards, background subtracted MFI values were used
for the subsequent analysis.
Inter- and intra-assay precision
Intra-assay precision was calculated as the average coef-
ficient of variation (CV) between triplicates. MFI signals
for each biomarker were measured in triplicate for 20 sam-
ples. The % CV for each sample was calculated between
the triplicates. The average of the individual CVs was re-
ported as the intra-assay CV. The intra-assay variability for
individual biomarkers was in the range of 3.1% to 8.1%.
The inter-assay precision was calculated from the
mean values for the high and low controls on each assay
plate. High and low controls for each biomarker were
run in triplicate on 4 different days to monitor day-to-
day variation. The plate means for high and low controls
were calculated and then used to calculate the overall
mean, standard deviation, and overall % CV. The average
of the high and low % CV was reported as the inter-
assay CV. Inter-assay precision for individual biomarkers
was in the range of 2.6% to 14.1%. Thus, inter- and
intra-assay reproducibility meets precision industry stan-
dards for these immunoassays.
Statistical methods
Logistic regression was used to develop a composite
panel of 4 biomarkers to distinguish between matched
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matched validation (n = 150) set. The logistic regression
models (PROC LOGISTIC, SAS; Cary, NC) were fitted
by comparing biomarker levels (CEA, CA125, CYFRA
21–1 and NY-ESO-1) in LC cases and controls. The
4 biomarkers were tested separately and a composite
score for the panel was determined using 3 approaches:
(1) multiple of median (MoM) in which the data from
each biomarker was converted to a multiple of a popula-
tion median value by dividing by the median value of the
control group; (2) multiple logistic regression (MLR)
using the data from the biomarker panel and; (3) training
set weightings from a multiple logistic regression of the
z-transformed data from each biomarker predicting can-
cer versus control outcome.
The area under the receiver operator characteristic
(ROC) curve (AUC) analysis was used to compare the
diagnostic power of each approach. To determine sam-
ple size, an AUC with a null hypothesis (Ho) set at 0.5
was used as the benchmark. A statistical power analysis
found that a sample size of 150 (75 control and 75 cases)
would provide 90% power to detect an AUC of 0.7, the
lowest AUC considered of clinical significance, from the
null AUC of 0.5 [47]. The cohort was used to create a
training data set and a matched validation data set. A
sample size of 230 (115 controls and 115 cases) was used
in the training data set and 150 (75 controls and 75
cases) was used in the validation set. The training set
was used to develop the LC predictive model and the
validation set was used to test the model developed. An
AUC analysis was used to determine sensitivity and cut-
off point value at 80% specificity.
Biomarker panel selection
The work presented here is based on preliminary studies
performed at Abbott Molecular, Inc, in which a large
number of biomarkers were employed to screen for a
wide array of lung cancer types. The primary conclusion
provided by this initial work is that, to date, even assays
that detect panels of several tumor protein markers do
not produce sufficient sensitivity for early-stage disease
detection. However, the addition of autoantibody detec-
tion to the assay increases the performance levels of a
biomarker panel for early detection due to the fact that
autoantibodies develop early in the oncogenesis process
and are thus stage independent, unlike tumor protein
biomarkers [37-39]. Thus, even at early stages of cancer,
when tumors are small and there is a lower concentra-
tion of circulating biomarkers, the production of anti-
bodies as part of the body’s response to the presence of
cancerous cells is robust and amplified.
The primary approach for selecting cancer autoanti-
bodies was via protein array technology, which utilizes
microarrays of large numbers of full-length proteins.Researchers from Abbott Molecular, Inc. used the Proto-
Array protein microarray from Invitrogen for discovery
of autoantibodies for early detection of LC. Invitrogen’s
ProtoArray (5000 proteins) was screened with sera from
NSCLC patients, individuals with benign lung disease
and apparently healthy controls. Autoantibodies were
identified that discriminated cancer from benign and
normal individuals. The criteria used for selection was
that the individual autoantibodies must have comple-
mentary performance. That is, a high percentage of the
cancer samples tested were detected with at least one of
the autoantibodies in the selected autoantibody array.
Multivariate analyses (decision tree (CART) and principal
component analysis) were used to confirm the comple-
mentarity of the autoantibodies selected. This screening
effort identified 4 auto-antigens that help discriminate
cancer from benign lung disease and normal individuals.
Two of them, MAPKAP3 and Cyclin E2, showed the best
discrimination. Other antigens known to elicit auto-
immune responses in cancer patients, such as p53 and
NY-ESO-1, were also included in the study.
This research led to the development of a panel of 8
biomarkers capable of early detection of LC, which in-
cluded tumor protein markers (CA125, CEA, CYFRA
21–1, and Pro-GRP) and 4 autoantibodies (MAPKAP3,
Cyclin E2, p53, and NY-ESO-1) [48].
Markers were carefully chosen to complement each
other. All tumor biomarkers (CA125, CEA, CYFRA 21–
1, and Pro-GRP) from the final panel have been exten-
sively studied and validated by others and are currently
in clinical use for monitoring of other cancers. CA125
and CEA were measured on the Architect instrument,
CYFRA 21–1 on the Elecsys 2010 system, and Pro-GRP
on a commercially available ELISA kit (Advanced Life
Science Institute Inc., Japan). Individual assays for the 4
identified autoantibodies were developed on Luminex
platform.
Eight markers have subsequently demonstrated high
levels of performance in multiple sample sets from inde-
pendent centers. During this discovery and development
period, a population of 782 people including 264 NSCLC
cases representing all stages of disease, 270 biopsy-
confirmed benign lung diseases, and 242 healthy smoker
controls matched for gender, age, and smoking history,
were studied. These serum samples were divided into 3
independent cohorts—1 for the development of marker
panels, and the other 2 (a training set and a test set) for
validation of those panels. Of these samples, a total of
245 met PAULA’s acceptance criteria (127 NSCLC cases
and 118 controls). Early-stage NSCLC was distinguished
from controls (e.g., benign lung disease and normal) with
an AUC of 0.84, and 72% sensitivity at 80% specificity.
Among the noncancerous patients, the specificity of
the 8-marker test was not greatly affected by either
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diseases (including asthma, COPD, emphysema, fibrosis,
and pneumonia), all of which yielded scores in the same
proportions as the overall normal population. 145 sam-
ples from 3 other high incidence cancer types (prostate,
breast, and colorectal) were tested by Abbott group to
ascertain the specificity of the test. Analysis of this
“other cancer” group (that was left out of the control
population for determination of the AUC and cutoff )
demonstrated that these other cancers yielded a higher
score more often than noncancerous conditions, yielding
a specificity of 66% and sensitivity of 34%.
There were deficiencies with the 8-marker method
that precluded it from being ready for clinical use. The
most intractable problem was that the panel was run on
several platforms with different detection technologies,
making it impractical for commercial use. We also found
that by removing 3 autoantibodies and the Pro-GRP
protein tumor biomarker, leaving a 4-biomarker panel
(CA125, CEA, CYFRA 21–1, and NY-ESO-1), assay per-
formance was maintained at levels similar to the 8-
marker panel, but with reduced labor and material costs.
This reduced panel contains a set of biomarkers that
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In this study, the objective was to evaluate the diagnostic
accuracy of PAULA’s test in detecting early stages of
NSCLC using our current 4-biomarker panel. The goal
was to identify early tumors in high-risk patients
(smokers or former smokers) where disease is curable.
Two independent studies were performed. Each of the
studies investigated serum sample types with known
diagnoses and outcomes. Results from the first study
(training set) were used to develop a classification
method for the samples that was then applied to the sec-
ond study (validation set).
The training set consisted of 230 samples and included
115 histopathologically confirmed early (stage I and II)
NSCLC cases (96.5%) and 3.5% stage III cancers
(Table 1). The LCs consisted of 38% squamous cell car-
cinoma, 36% adenocarcinoma, 17% large cell carcin-
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The control cohort included 115 serum samples from
healthy risk-matched volunteers (Table 1).
The validation set consisted of 150 samples and in-
cluded 75 NSCLC patients from the high-risk population
and 75 normal controls. 50 NSCLC cases were histo-
pathologically confirmed as early stages I or II (67%) and
25 cases (33%) were stages III and IV (Table 1). Similar
to the training set, this validation set included a range of
LC histologies: 32 adenocarcinomas, 21 bronchioloalveo-
lar carcinomas, 4 carcinomas not otherwise specified
(NOS), 1 large cell neuroendocrine carcinoma, and 2 un-
identified LCs. The clinical and demographic character-
istics of the cases and control patients comprising this
set are summarized in Table 1.
Training set
ROC curves from a logistic regression analysis were used
to evaluate the capability of each of the 4 biomarkers to
discriminate between LC cases and controls. The indi-
vidual biomarkers exhibited AUC values in the range of
0.60–0.79 (Table 2; Figure 1A), where the highest AUC
from an individual biomarker was found for CEA (0.79;
Table 2; Figure 1A). The combined panel of 4 bio-
markers (NY-ESO-1, CEA, CA125, and CYFRA 21–1)
provided a model with an improved, higher AUC at 0.83
(Table 2; Figure 1A). The MoM analysis resulted in simi-
lar AUC values to ones from a logistic regression ana-
lysis (Table 2A and B). All individual and combined
biomarker panels provided AUCs that were significantly
higher than the null of 0.50 (p < 0.05; Table 2). ForTable 2 ROC curve area comparison
A. From a logistic regression analysis
Biomarker Transformation AUCa Standard
NY-ESO-1 Raw 0.60 0.04
CEA Raw 0.79 0.03
CA125 Raw 0.70 0.03
CYFRA 21-1 Raw 0.69 0.04
4 Biomarker Modelc Raw 0.83 0.03
B. From a MoM analysis
Biomarker Transformation AUCa Standard
NY-ESO-1 Raw 0.60 0.04
CEA Raw 0.79 0.03
CA125 Raw 0.70 0.03
CYFRA 21-1 Raw 0.69 0.04
4 Biomarker Modelc Raw 0.81 0.03
aAUC.
bProbability of difference to AUC = 0.5.
c4 Biomarker model = NY-ESO-1, CEA, CA125, and CYFRA 21-1.example, the data from combined biomarker panel gave
an AUC of 0.81 using MoM analysis (Figure 1B).
The sensitivity and specificity of individual biomarkers
and the combined 4 biomarker panel in the training set
were evaluated using both MOM and MLR analysis,
which gave very similar results. For example, MOM ana-
lysis showed 63%, 42%, 45%, and 47% sensitivity at 80%
specificity for CEA, CA125, CYFRA 21–1, and NY-ESO-
1, respectively. Although the expressions of each of these
4 biomarkers are elevated in serum of a proportion of
patients with LC, they are not sensitive or specific
enough to reliably detect asymptomatic patients with LC
when considered individually. Combining the tumor
antigens (CEA, CA125, and CYFRA 21–1) with the NY-
ESO-1 autoantibody marker provides the panel with
significantly enhanced sensitivity (73% at 80% fixed
specificity) using a cutoff of 6.4. Samples with the aggre-
gate score above this cutoff were considered positive.
There was no indeterminate zone in this study. The 4-
biomarker panel appears to have good discriminating
power to differentiate control patients from LC patients
with AUC of 0.81 using MoM method and AUC of 0.83
using MLR analysis (Figure 1A and B).
Validation set
To further evaluate the diagnostic performance of the 4-
biomarker models, the logistic regression parameter esti-
mates and median results for the MoM transformation
developed for the training set were applied to predict
cancer and control outcomes of the validation data set.














Figure 1 ROC curve analyses of training data set (n = 230) (A and B) and validation set (n = 150) (C and D). Panel A shows ROC curves for
prediction of LC using multiple logistic regression weightings for each individual biomarker and a model combining all 4 biomarkers. The AUC
values are 0.60, 0.79, 0.70, 0.69, and 0.83 for NY-ESO-1, CEA, CA125, CYFRA 21–1, and the combined panel, respectively; Panel B is a ROC curve
generated from the 4-biomarker panel using the MoM scoring method (AUC value = 0.81); Panel C shows a ROC curve of the validation set for
prediction of LC using the MLR method (AUC = 0.82), and Panel D shows the same data using MoM transformation (AUC = 0.85).
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scriptive statistics for each of the biomarkers are given
for the training and validation data sets (Table 3). The
combined 4 biomarker panel applied to the validationcohort provided an AUC of 0.82 using the MLR
method (p < 0.0001, see Figure 1C). The MoM trans-
formation provided a higher AUC of 0.85 (p < 0.0001,
see Figure 1D).
Table 3 Expression levels of biomarkers CEA (ng/ml), CA125 (U/ml), CYFRA 21-1 (ng/ml), and NY-ESO-1 (MFI) for LC
cases and matched controls in the training (n=230) and validation (n=150) data sets
Biomaker Statistic cancer_train cancer_valid control_train control_valid
CA125 N 115.00 75.00 115.00 75.00
Mean 16.76 42.18 9.55 8.47
StdDev 18.85 135.95 7.71 7.29
Min 2.19 3.56 0.00 0.00
Max 170.10 1181.4 41.77 54.96
CEA N 115.00 75.00 115.00 75.00
Mean 6.81 9.60 1.35 1.41
StdDev 13.87 18.01 0.85 1.03
Min 0.34 0.25 0.04 0.00
Max 93.37 71.35 6.28 5.96
CYFRA 21-1 N 115.00 75.00 115.00 75.00
Mean 15.58 4.60 5.93 1.93
StdDev 55.49 4.34 9.67 1.73
Min 0.00 0.00 0.00 0.00
Max 553.85 21.88 89.09 7.17
NY-ESO-1 N 115.00 75.00 115.00 75.00
Mean 158.17 133.00 49.76 55.68
StdDev 442.34 290.50 71.12 63.24
Min 3.37 4.00 3.33 0.00
Max 3298.3 1890.8 417.70 420.33
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ation data set than MLR (Figure 1C and D) and, at a speci-
ficity of 80%, the MoM 4-biomarker model provided a
higher sensitivity as well (77% vs 68%). Holding the training
cutoff at 6.4 resulted in an estimate of 71% sensitivity and
88% specificity. Overall, the validation set data support the
classification that was determined from the training set and
confirmed the ability of the 4-biomarker panel to distin-
guish early-stage cancers from normal controls. All subse-
quent analysis was performed using the MoM method.
Diagnostic performance
The validation and training sets were combined to calculate
the sensitivity of individual biomarkers at fixed 80% specifi-
city using the MoM method (n = 380). ROC analysis of the
combined 4-biomarker panel resulted in 74.2% sensitivity
and 80% specificity of NSCLC detection corresponding to a
6.1 cutoff (AUC= 0.83). Applying the classification cutoff of
6.4 from the training set yielded a sensitivity of 72% and a
specificity of 83% for the combined set. As before, the indi-
vidual performances of the four biomarkers showed insuffi-
cient sensitivity at 80% specificity (data not shown).
Performance of the 4-biomarker panel in the com-
bined data set was further characterized through analysis
of final PAULA’s scores distribution by tumor stage and
tumor histology (Figure 2A and B).Within the LC group, PAULA’s test scores were grouped
according to stages and histological types (Table 4). Early
stages (I and II) were detected with less sensitivity and
diagnostic accuracy than late stages (71.2% sensitivity and
AUC 0.82, p < 0.0001 versus 76.7% sensitivity and AUC
0.87, p < 0.0001). Patients with bronchioalveolar and large
cell carcinoma (which included 17 cases of large cell
neuroendocrine carcinoma subtype, LCNEC) were de-
tected with the highest sensitivity (85.7% and 75%) and
diagnostic accuracy (AUC 0.89 and 0.84, respectively).
The most prevalent NSCLC types, adenocarcinoma and
squamous cell carcinoma (SCC), demonstrated similar
performance in this study (sensitivities 69% and 70%;
AUC 0.82 and 0.80, respectively, p < 0.0001) (Table 4).
17 neuroendocrine specimens included in our com-
bined sample set belong to the large cell neuroendo-
crine carcinoma (LCNEC) which is now recognized as a
histologically high-grade NSCLC [49]. Similar to SCLC,
LCNEC is a fast-growing type of cancer which repre-
sents challenges in early detection and diagnosis. It ac-
counts for approximately 1.6–3.1% of all lung cancer
[50]. The LCNEC samples were overrepresented in our
LC cases (9.4%). However, they did not affect overall
performance of a combined set. When analyzed separ-
ately by ROC analysis LCNEC subtype yielded an AUC
of 0.84.
Figure 2 Distribution of PAULA’s test scores by NSCLC stage (A) and by histological types (B) using MoM model. The red horizontal lines
show the PAULA’s test cut-off of 6.4 derived from training set results.
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physician as to the probability of LC and determine the
appropriate follow-up procedures based on that prob-
ability. Therefore, it is important to know the probability
that the test result will give the correct diagnosis. PPV is
the proportion of people with a positive test result, ei-
ther above the MoM or MLR cut off at 80% specificity,
who have LC. Assuming a LC prevalence of 2%, a higher
proportion of people who have the disease will have a
positive test result using the MoM model (7.2%) than
the MLR model (6.5%). The NPV is the proportion of
people with a negative test result who do not have the
disease, which was above 99% for both tests.
PAULA’s test performance with benign lung diseases and
other cancers
To assess the validity of our biomarker panel for discrim-
ination of benign lung conditions from the healthy patientTable 4 Performance of PAULA’s test in the combined set (tra
4-biomarker MoM aggregate scores
Number of cases Cutoff
Early stages (I & II) 160 6.4
Late stages (III & IV) 30 6.4
Total 190
Adenocarcinoma 73 6.4
Squamous cell carcinoma 60 6.4
Bronchioalveolar carcinoma 28 6.4
Large cell (incl. LCNEC) 20 6.4
Carcinoma, NOS 5 6.4
Other 4
Total 190control group, a separate cohort of 81 sera with benign
conditions and other cancers was tested using PAULA’s
test. Elevated PAULA’s scores (>6.4 cutoff) were found in
9 serum samples (11%). The scores above the 6.4 cutoff
were most frequently detected in patients with COPD: 5
out of 9 false-positive cases. PAULA’s score was also ele-
vated in patients with pneumonia (1), asthma (1), inflam-
mation A (1) and in the case of multiple myeloma (1).
Increased expression of CEA and CYFRA 21–1 bio-
markers was responsible for the majority of the false
positives: 7 out of 9 cases had increased CEA, and 4 out
of 9 cases had elevated CYFRA 21–1 expression. NY-
ESO-1 autoantibody biomarker was expressed in the
serum of a patient with multiple myeloma.
Discussion
There has been a wealth of recent literature in which the
utility of tumor protein-based biomarker or autoantibodyining plus validation) using ROC AUC analysis of
AUC P value % sensitivity at 83% specificity
0.82 < 0.0001 71.2
0.87 < 0.0001 76.7
0.82 < 0.0001 69.0
0.80 < 0.0001 70.0
0.89 < 0.0001 85.7
0.84 < 0.0001 75.0
0.85 0.0069 60.0
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Historically, the primary impediments to employment of
these types of assays in clinical testing have been (1) insuf-
ficient specificity, especially using panels with a limited
number of biomarkers; and (2) insufficient sensitivity and
reproducibility between sample sets.
Our unique approach involves measuring the levels of
both of these 2 distinct types of analytes circulating in the
blood, tumor antigens and autoantibodies, and using a
MoM algorithm to generate a score categorizing the risk
that the patient has LC based on the expression of a specific
combination of these analytes. This defined combination
has the benefit of increasing the sensitivity and specificity of
this test as compared to using each analyte type alone.
20/20’s panel is derived from an original 8-biomarker
panel that had been previously identified [48]. The
markers selected were 3 tumor proteins (CEA, CA125,
CYFRA 21–1) supplemented by NY-ESO-1 autoanti-
bodies. Each of the above tumor protein markers has
been extensively characterized individually and validated
in the scientific literature [51-67]. Overall, the perform-
ance of each biomarker included in our study, when ana-
lyzed individually, was similar to what has previously
been reported in the literature.
CYFRA 21–1 (cytokeratin 19) has been proposed as
an independent and sensitive tumor marker for NSCLC
since 1993 [51,52]. It has a high diagnostic sensitivity for
the detection of NSCLC, especially squamous cell car-
cinoma (SCC) [19,51-53]. In most cases increased ex-
pression levels of CYFRA 21–1 in the blood correlate
with the stage of the disease, which can be used for
prognostic purposes [54-57]. The prognostic value of
serum CYFRA 21–1 levels in NSCLC was estimated in a
paper by Pujol et al. [56] where 2063 NSCLC patients
data were examined using a meta-analysis of several
studies. Results of this analysis showed that an elevated
pretreatment CYFRA 21–1 level (>3.6 ng/mL) was an
unfavorable prognostic factor in NSCLC. Using 3.3 ng/ml
as the cutoff, abnormal CYFRA 21–1 levels were found by
Molina et al. in 65.6% of patients with NSCLC [58]. Based
on our data, CYFRA 21–1 detected NSCLC with
47.4% sensitivity at 80% fixed specificity and AUC
0.69 (p < 0.0001) when considered alone, which corre-
sponded to a cutoff of 5.1 ng/ml.
Several studies have indicated that CYFRA 21–1 has a
better sensitivity for squamous cell carcinoma than other
histologies [59]. We also observed higher diagnostic
value for CYFRA 21–1 in detecting SCC (AUC 0.71)
than adenocarcinoma (AUC 0.63), p <0.0001. However,
in our study CYFRA 21–1 expression was most fre-
quently observed in large cell carcinoma (including large
cell neuroendocrine carcinoma), resulting in the highest
diagnostic accuracy for detecting this histological type
(AUC 0.81) compared to other NSCLC subtypes.CEA is another tumor marker that has been evaluated
for its ability to contribute to NSCLC detection [19,60,61]
It has relatively high sensitivity for many advanced adeno-
carcinomas, including lung adenocarcinoma [60]. Several
studies have reported that elevated CEA levels indicate
poor prognosis in patients with NSCLC, even for
those with stage I diagnosis [57,62,63]. Okada et al. [63]
measured serum CEA levels in 1,000 NSCLC patients, be-
fore and after tumor resection, and found that elevated
levels of preoperative CEA correlated with significantly
lower 5-year survival compared to patients with normal
levels (53.8% versus 75.2%; p < 0.0001). Our data show that
CEA has elevated levels (higher than 3 ng/ml) in 46.3% of
NSCLC cases (n = 190) and 4.7% of normal controls
(AUC = 0.77, p < 0.0001). Similar to previous observa-
tions, in our study CEA detected adenocarcinoma
(using 3 ng/ml cutoff ) with a higher sensitivity and
diagnostic accuracy than SCC (53.5% versus 40% and
AUC 0.8 versus 0.74, respectively). Seventy-five % of the
patients with large cell tumors also had elevated CEA
levels (>3 ng/ml). This biomarker demonstrated the best
sensitivity and diagnostic accuracy, when taken alone, of
all the biomarkers evaluated in our study.
The CA125 biomarker has been widely researched as
well and mainly used for monitoring ovarian cancer [64].
However, LC can also cause elevated levels of CA125
[19,61,65]. Among LC types, abnormal CA125 serum
levels were most often found in adenocarcinoma and
large-cell LC [19,59,63]. In our study, CA125 was ele-
vated above normal levels (>35 U/ml) in 18% of NSCLC
serums (n = 190) and only in 2% of normal controls
(n = 190). CA125 biomarker sensitivity was the highest in
bronchioalveolar carcinoma subtype: 36% of cases had
CA125 level higher than 35 U/ml. The tumor markers
from our panel had varied sensitivities for different histolo-
gies, which could aid in distinguishing the type of NSCLC.
Additionally, in agreement with the literature reports, the
expression of these biomarkers was higher in advanced
NSCLC stages as compared to early stages.
Many studies have reported that autoantibodies appear
before apparent clinical signs of LC [37-39]. Therefore,
they can be detected in serum of patients with the
asymptomatic, early stages of cancer. The presence of
antibodies to NY-ESO-1 has also been correlated with
the progression towards malignancy and worse progno-
sis in patients with NSCLC [38,64,65]. In this study NY-
ESO-1 autoantibodies, when measured individually, had
43% sensitivity at 80% specificity with respect to NSCLC
detection. The expression of NY-ESO-1 was much higher
in the bronchioalveolar carcinoma subtype, compared to
adenocarcinoma and squamous cell carcinoma (82.1%,
42.5%, and 36.7%, respectively). It was not expressed in the
neuroendocrine subtype of large cell carcinoma. The sensi-
tivity of early NSCLC stages detection by NY-ESO-1
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stage detection (44.7% versus 34.5%, respectively). How-
ever, similar to previous observations, no single biomarker
analyzed in our study showed sufficient sensitivity for
early-stage disease detection when measured individually.
The primary insight provided by the initial work in
biomarker panel selection was the realization that even
assays that detect panels of several tumor protein
markers provide inconsistent results with respect to reli-
able cancer detection in its early stages. The addition of
autoantibody detection to the assay may identify cancer at
an early stage due to the fact that autoantibody expression
is stage independent. Thus, we combined 3 tumor pro-
teins (CEA, CA125, and CYFRA 21–1) with NY-ESO-1
autoantibodies and were able to improve NSCLC detec-
tion sensitivity. The results of ROC analysis using aggre-
gate MoM score demonstrated that our 4-biomarker
panel was able to discriminate cases from controls with
72.7% and 82.8% sensitivity at 80% specificity for early-
and late-stage NSCLC respectively. NY-ESO-1 autoanti-
bodies in addition to 3 tumor markers resulted in the
increase of overall sensitivity of NSCLC detection (from
67.9% for 3 tumor markers combined to 74.2% for 4-
biomarker panel), which was mainly due to the increased
sensitivity of early-stage detection (from 65.2% to 72.7%,
respectively). For LC prevalence in a high-risk population
of approximately 2% [68] this performance would result in
a PPV of 7.2% and an NPV of 99.4%. We believe that the
clinical performance of the PAULA’s test, as well as its
simple and easy-to-use format, makes it suitable for use as
an aid to CT screening.
An interesting observation is that the combination of
selected markers provides only a moderate (though
important) improvement in assay performance (AUC,
sensitivity, specificity) in the current PAULA’s test, as
compared to the best individual markers considered
alone. This behavior is commonly observed in the devel-
opment of tumor protein-based assay panels for cancer
detection. This indicates that most tumors overlap con-
siderably in the tumor protein markers they express,
suggesting that in most cases the assembly of a tumor
protein marker panel will be a challenging exercise.
Interestingly, there is evidence that autoantibodies are
not so redundant, meaning patients positive for one are
not often positive for another (from Abbott biomarker
selection studies described in Materials and methods,
data not shown). This may turn out to be an additional
advantage of the mixed tumor protein/autoantibody
panel, when additional autoantibodies are added to
the present PAULA’s panel.
There are 2 possible scenarios for the placement of an
adjunct to CT LC blood test: (1) before diagnostic CT,
to predict the risk of LC in order to enrich the popula-
tion being offered CT scan; and (2) after CT, to improveinterpretation of CT images in the setting of suspicious
pulmonary nodules.
In this study we investigated whether we could detect
early stages of NSCLC using our current 4-biomarker
panel. The goal was to identify early tumors in high-risk
patients (smokers or former smokers) where disease is
curable. Consequently, the majority of cancers in the
training and validation sets were retrospective samples
from stages I and II. The study’s control population
was matched by smoking history, age, and gender
and represented people with no history of cancers or
other diseases.
We understand the need for studies involving an ap-
propriate control population, such as serum from pa-
tients with pulmonary diseases and other cancers, to
fully evaluate the current biomarker panel. For this rea-
son we separately tested an additional sample cohort
comprised of 81 serum samples from patients with be-
nign diseases (COPD, asthma, bronchitis, pulmonary
fibrosis, etc.) and other cancers, including myeloma,
breast and colon cancers. We found that PAULA’s test
score was above the 6.4 cutoff in 11% of serums from
this set. This misclassification was expected due to pre-
vious reports in the literature where increased expres-
sion of some of these biomarkers was observed in
benign pulmonary diseases [69-71] and other cancers. In
the benign diseases cohort, 5 out of 8 false positives
were COPD cases. Thus, COPD could potentially yield
a higher score than normal controls in our test. Previous
studies indicate that approximately 20% of heavy
smokers develop COPD and the prevalence of this
disease is around 50% in patients who had newly di-
agnosed lung cancer [72]. In addition, it was docu-
mented that COPD is an independent risk factor for
lung cancer. Therefore, if among false positives for
PAULA’s test COPD cases were detected, it should be
recognized that this represents the probability that an in-
dividual will have lung cancer, and these data should be
interpreted cautiously. Elevated PAULA’s scores were also
found in patients with 3 other non-neoplastic conditions
(pneumonia, asthma, and chronic inflammation), con-
firming that some inflammatory conditions can modify
our biomarkers measurement.
As one of the limitations of the present study, samples
with benign pulmonary nodules were not included
among the controls. There were 2 primary reasons for
this omission: (1) It is difficult and expensive to gain ac-
cess to serum samples from patients with well character-
ized pulmonary nodules; and (2) we were not attempting
to establish the correlation between positive PAULA’s
test and the presence of CT nodules in this study.
The samples used in our study do not represent the
expected distribution of cancer types, stages, or the fre-
quency of benign diseases that one would see in the
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common problem with the usage of archived sample sets
in validation studies such as this, and slightly altered
performance must be expected when implementing this
test in the general population. There is no reason to
expect that these results are not predictive of real-life
performance when PAULA’s test is implemented as a
clinical test. Nevertheless, a prospective study will be
required to further validate the utility of PAULA’s
assay for clinical use. We are currently testing clinical
samples from the high-risk population in our CLIA
lab. The follow-up information from the positives by
the PAULA’s test cases is being collected and will help
to estimate the test’s clinical utility with an intended
use population.
To further increase the sensitivity and specificity of
this panel in the detection of early LC stages, the
addition of other biomarkers (autoantibodies and tumor
proteins) to our present panel is currently in develop-
ment by our laboratory. The current biomarker panel
will be refined as follow-up data accrue. We anticipate
that future additions of new biomarkers will result in a
better clinical performance.Conclusion
In conclusion, we have presented a validation study of
20/20’s PAULA’s test that effectively distinguished
NSCLC cases from normal patients and patients with
benign pulmonary diseases. Based on these and previous
data we believe that the performance of the PAULA’s
test makes it suitable for use as an aid to LDCT screen-
ing. The complementary use of an annual blood-based
biomarker test to establish a suspicion of cancer risk be-
fore patients would be subjected to CT holds great
promise for the early detection of LC, leading to a re-
duction in the disease-specific mortality rate. There re-
mains a great deal of controversy regarding LDCT
screening at many levels, including long-term radiation
exposure, the high number of false positives, lack of
standardization of the LDCT procedure, and analysis
outside of a clinical trial environment. For physicians, a
serum test that could be used as a screening tool to
identify patients with suspected asymptomatic LC and
guide them to seek secondary (diagnostic) CT screening
is urgently needed. As noted, our data suggest this
would be a productive strategy. From a healthcare per-
spective, such pre-enrichment of cancer risk prior to CT
would in effect avoid a portion of false positive CT re-
sults and consequent workups, and would enhance the
cost effectiveness of screening.Competing interests
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